Infectious Disease

Colchicine Reduces Hospital Keep And Loss of life In COVID-19

January 25, 2021

1 min read

Source / information

Disclosure:
COLCORONA was funded by the Quebec government, the NHLBI / NIH, Montreal philanthropist Sophie Desmarais, and the COVID-19 Therapeutics Accelerator, an initiative of the Bill and Melinda Gates Foundation, Wellcome, and Mastercard. CGI, Dacima and Pharmascience from Montreal were also contributors to the study. Tardif does not report any relevant financial information.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

Colchicine reduced hospital stay and mortality in patients with COVID-19 by more than 20%. This is evident from the results of the randomized COLCORONA study.

According to a press release from the Montreal Heart Institute, the COLCORONA study suggests that colchicine, an anti-inflammatory drug primarily used to treat gout, can prevent a cytokine storm and other complications in patients with COVID-19 compared to placebo.

Source: Adobe Stock

Treating higher-risk patients with colchicine once a confirmed diagnosis of COVID-19 was made reduced the risk of developing a severe form of the disease and subsequently reduced the number of hospitalizations, according to the press release.

For the contactless, randomized, double-blind, placebo-controlled study, researchers in Canada, the United States, Europe, South America, and South Africa evaluated the effectiveness of colchicine in reducing the risk of serious complications associated with COVID-19. COLCORONA included approximately 4,488 patients with COVID-19 and at least one other risk factor for COVID-19 complications who were not hospitalized at the time of admission.

In the overall cohort, colchicine reduced death or hospitalization by 21% compared to placebo, a result that “approached statistical significance” according to the press release.

In an analysis of 4,159 patients with a confirmed diagnosis of COVID-19 from a nasopharyngeal PCR test compared to placebo, colchicine reduced hospital admissions by 25%, the need for mechanical ventilation by 50%, and mortality by 44%, and these results were statistically significant, according to the publication.

Jean-Claude Tardif

“Our research shows the effectiveness of colchicine treatment in preventing the ‘cytokine storm’ phenomenon and reducing the complications associated with COVID-19.” Jean-Claude Tardif, MD, Director of the research center of the Montreal Heart Institute and professor of medicine at the Université de Montréal, said in the press release. “We are proud to offer the world’s first oral drug whose use can have a significant public health impact and potentially prevent COVID-19 complications in millions of patients.”

As Healio previously reported, colchicine has been shown to reduce the risk of CVD in high-risk patients from the COLCOT and LoDoCo2 studies.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

COVID-19 Resource Center

COVID-19 Resource Center

Related Articles